{"pmid":32463478,"title":"Treating the SARS-CoV-2-positive patient with cancer: A proposal for a pragmatic and transparent ethical process.","text":["Treating the SARS-CoV-2-positive patient with cancer: A proposal for a pragmatic and transparent ethical process.","The treatment of patients with cancer who test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses unique challenges. In this commentary, the authors describe the ethical rationale and implementation details for the creation of a novel, multidisciplinary treatment prioritization committee, including physicians, frontline staff, an ethicist, and an infectious disease expert. Organizational obligations to health care workers also are discussed. The treatment prioritization committee sets a threshold of acceptable harm to patients from decreased cancer control that is justified to reduce risk to staff. The creation of an ethical, consistent, and transparent decision-making process involving such frontline stakeholders is essential as departments across the country are faced with decisions regarding the treatment of SARS-CoV-2-positive patients with cancer.","Cancer","Perni, Subha","Milligan, Michael G","Saraf, Anurag","Vivenzio, Todd","Marques, Amy","Baker, Meghan A","Kosak, Tara","Bartlett, Sarah","Physic, Michelle A","Batchelder, Monica R","McBride, Sean","Bredfeldt, Jeremy","Cail, Daniel W","Kearney, Meghan C","Whitehouse, Colleen","Orio, Peter","Walsh, Gerard","Haas-Kogan, Daphne A","Martin, Neil E","32463478"],"abstract":["The treatment of patients with cancer who test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses unique challenges. In this commentary, the authors describe the ethical rationale and implementation details for the creation of a novel, multidisciplinary treatment prioritization committee, including physicians, frontline staff, an ethicist, and an infectious disease expert. Organizational obligations to health care workers also are discussed. The treatment prioritization committee sets a threshold of acceptable harm to patients from decreased cancer control that is justified to reduce risk to staff. The creation of an ethical, consistent, and transparent decision-making process involving such frontline stakeholders is essential as departments across the country are faced with decisions regarding the treatment of SARS-CoV-2-positive patients with cancer."],"journal":"Cancer","authors":["Perni, Subha","Milligan, Michael G","Saraf, Anurag","Vivenzio, Todd","Marques, Amy","Baker, Meghan A","Kosak, Tara","Bartlett, Sarah","Physic, Michelle A","Batchelder, Monica R","McBride, Sean","Bredfeldt, Jeremy","Cail, Daniel W","Kearney, Meghan C","Whitehouse, Colleen","Orio, Peter","Walsh, Gerard","Haas-Kogan, Daphne A","Martin, Neil E"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32463478","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/cncr.32962","keywords":["bioethics","coronavirus disease 2019 (covid-19)","patient safety","quality improvement","radiation oncology"],"weight":0,"_version_":1668079521494990848,"score":9.490897,"similar":[{"pmid":32409625,"title":"'Your country needs you': the ethics of allocating staff to high-risk clinical roles in the management of patients with COVID-19.","text":["'Your country needs you': the ethics of allocating staff to high-risk clinical roles in the management of patients with COVID-19.","As the COVID-19 pandemic impacts on health service delivery, health providers are modifying care pathways and staffing models in ways that require health professionals to be reallocated to work in critical care settings. Many of the roles that staff are being allocated to in the intensive care unit and emergency department pose additional risks to themselves, and new policies for staff reallocation are causing distress and uncertainty to the professionals concerned. In this paper, we analyse a range of ethical issues associated with changes to staff allocation processes in the face of COVID-19. In line with a dominant view in the medical ethics literature, we claim, first, that no individual health professional has a specific, positive obligation to treat a patient when doing so places that professional at risk of harm, and so there is a clear ethical tension in any reallocation process in this context. Next, we argue that the changing asymmetries of health needs in hospitals means that careful consideration needs to be given to a stepwise process for deallocating staff from their usual duties. We conclude by considering how a justifiable process of reallocating professionals to high-risk clinical roles should be configured once those who are 'fit for reallocation' have been identified. We claim that this process needs to attend to three questions that we consider in detail: (1) how the choice to make reallocation decisions is made, (2) what justifiable models for reallocation might look like and (3) what is owed to those who are reallocated.","J Med Ethics","Dunn, Michael","Sheehan, Mark","Hordern, Joshua","Turnham, Helen Lynne","Wilkinson, Dominic","32409625"],"abstract":["As the COVID-19 pandemic impacts on health service delivery, health providers are modifying care pathways and staffing models in ways that require health professionals to be reallocated to work in critical care settings. Many of the roles that staff are being allocated to in the intensive care unit and emergency department pose additional risks to themselves, and new policies for staff reallocation are causing distress and uncertainty to the professionals concerned. In this paper, we analyse a range of ethical issues associated with changes to staff allocation processes in the face of COVID-19. In line with a dominant view in the medical ethics literature, we claim, first, that no individual health professional has a specific, positive obligation to treat a patient when doing so places that professional at risk of harm, and so there is a clear ethical tension in any reallocation process in this context. Next, we argue that the changing asymmetries of health needs in hospitals means that careful consideration needs to be given to a stepwise process for deallocating staff from their usual duties. We conclude by considering how a justifiable process of reallocating professionals to high-risk clinical roles should be configured once those who are 'fit for reallocation' have been identified. We claim that this process needs to attend to three questions that we consider in detail: (1) how the choice to make reallocation decisions is made, (2) what justifiable models for reallocation might look like and (3) what is owed to those who are reallocated."],"journal":"J Med Ethics","authors":["Dunn, Michael","Sheehan, Mark","Hordern, Joshua","Turnham, Helen Lynne","Wilkinson, Dominic"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32409625","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1136/medethics-2020-106284","keywords":["clinical ethics","health care for specific diseases/groups","health personnel","professional - professional relationship"],"weight":0,"_version_":1666897319172243456,"score":158.32237},{"pmid":32478867,"title":"Management of primary skin cancer during a pandemic: Multidisciplinary recommendations.","text":["Management of primary skin cancer during a pandemic: Multidisciplinary recommendations.","During the coronavirus disease 2019 (COVID-19) pandemic, providers and patients must engage in shared decision making regarding the pros and cons of early versus delayed interventions for localized skin cancer. Patients at highest risk of COVID-19 complications are older; are immunosuppressed; and have diabetes, cancer, or cardiopulmonary disease, with multiple comorbidities associated with worse outcomes. Physicians must weigh the patient's risk of COVID-19 complications in the event of exposure against the risk of worse oncologic outcomes from delaying cancer therapy. Herein, the authors have summarized current data regarding the risk of COVID-19 complications and mortality based on age and comorbidities and have reviewed the literature assessing how treatment delays affect oncologic outcomes. They also have provided multidisciplinary recommendations regarding the timing of local therapy for early-stage skin cancers during this pandemic with input from experts at 11 different institutions. For patients with Merkel cell carcinoma, the authors recommend prioritizing treatment, but a short delay can be considered for patients with favorable T1 disease who are at higher risk of COVID-19 complications. For patients with melanoma, the authors recommend delaying the treatment of patients with T0 to T1 disease for 3 months if there is no macroscopic residual disease at the time of biopsy. Treatment of tumors >/=T2 can be delayed for 3 months if the biopsy margins are negative. For patients with cutaneous squamous cell carcinoma, those with Brigham and Women's Hospital T1 to T2a disease can have their treatment delayed for 2 to 3 months unless there is rapid growth, symptomatic lesions, or the patient is immunocompromised. The treatment of tumors >/=T2b should be prioritized, but a 1-month to 2-month delay is unlikely to worsen disease-specific mortality. For patients with squamous cell carcinoma in situ and basal cell carcinoma, treatment can be deferred for 3 months unless the individual is highly symptomatic.","Cancer","Baumann, Brian C","MacArthur, Kelly M","Brewer, Jerry D","Mendenhall, William M","Barker, Christopher A","Etzkorn, Jeremy R","Jellinek, Nathaniel J","Scott, Jeffrey F","Gay, Hiram A","Baumann, John C","Manian, Farrin A","Devlin, Phillip M","Michalski, Jeff M","Lee, Nancy Y","Thorstad, Wade L","Wilson, Lynn D","Perez, Carlos A","Miller, Christopher J","32478867"],"abstract":["During the coronavirus disease 2019 (COVID-19) pandemic, providers and patients must engage in shared decision making regarding the pros and cons of early versus delayed interventions for localized skin cancer. Patients at highest risk of COVID-19 complications are older; are immunosuppressed; and have diabetes, cancer, or cardiopulmonary disease, with multiple comorbidities associated with worse outcomes. Physicians must weigh the patient's risk of COVID-19 complications in the event of exposure against the risk of worse oncologic outcomes from delaying cancer therapy. Herein, the authors have summarized current data regarding the risk of COVID-19 complications and mortality based on age and comorbidities and have reviewed the literature assessing how treatment delays affect oncologic outcomes. They also have provided multidisciplinary recommendations regarding the timing of local therapy for early-stage skin cancers during this pandemic with input from experts at 11 different institutions. For patients with Merkel cell carcinoma, the authors recommend prioritizing treatment, but a short delay can be considered for patients with favorable T1 disease who are at higher risk of COVID-19 complications. For patients with melanoma, the authors recommend delaying the treatment of patients with T0 to T1 disease for 3 months if there is no macroscopic residual disease at the time of biopsy. Treatment of tumors >/=T2 can be delayed for 3 months if the biopsy margins are negative. For patients with cutaneous squamous cell carcinoma, those with Brigham and Women's Hospital T1 to T2a disease can have their treatment delayed for 2 to 3 months unless there is rapid growth, symptomatic lesions, or the patient is immunocompromised. The treatment of tumors >/=T2b should be prioritized, but a 1-month to 2-month delay is unlikely to worsen disease-specific mortality. For patients with squamous cell carcinoma in situ and basal cell carcinoma, treatment can be deferred for 3 months unless the individual is highly symptomatic."],"journal":"Cancer","authors":["Baumann, Brian C","MacArthur, Kelly M","Brewer, Jerry D","Mendenhall, William M","Barker, Christopher A","Etzkorn, Jeremy R","Jellinek, Nathaniel J","Scott, Jeffrey F","Gay, Hiram A","Baumann, John C","Manian, Farrin A","Devlin, Phillip M","Michalski, Jeff M","Lee, Nancy Y","Thorstad, Wade L","Wilson, Lynn D","Perez, Carlos A","Miller, Christopher J"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32478867","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/cncr.32969","keywords":["merkel cell carcinoma","mohs surgery","basal cell carcinoma","coronavirus disease 2019 (covid-19)","cutaneous squamous cell carcinoma","melanoma","radiotherapy","skin cancer","treatment delays"],"locations":["Merkel"],"topics":["Prevention"],"weight":1,"_version_":1668437835182505984,"score":156.15211},{"pmid":32286909,"title":"COVID-19 Pandemic: What Every Otolaryngologist-Head and Neck Surgeon Needs to Know for Safe Airway Management.","text":["COVID-19 Pandemic: What Every Otolaryngologist-Head and Neck Surgeon Needs to Know for Safe Airway Management.","The novel coronavirus disease 2019 (COVID-19) pandemic has unfolded with remarkable speed, posing unprecedented challenges for health care systems and society. Otolaryngologists have a special role in responding to this crisis by virtue of expertise in airway management. Against the backdrop of nations struggling to contain the virus's spread and to manage hospital strain, otolaryngologists must partner with anesthesiologists and front-line health care teams to provide expert services in high-risk situations while reducing transmission. Airway management and airway endoscopy, whether awake or sedated, expose operators to infectious aerosols, posing risks to staff. This commentary provides background on the outbreak, highlights critical considerations around mitigating infectious aerosol contact, and outlines best practices for airway-related clinical decision making during the COVID-19 pandemic. What otolaryngologists need to know and what actions are required are considered alongside the implications of increasing demand for tracheostomy. Approaches to managing the airway are presented, emphasizing safety of patients and the health care team.","Otolaryngol Head Neck Surg","Balakrishnan, Karthik","Schechtman, Samuel","Hogikyan, Norman D","Teoh, Anthony Y B","McGrath, Brendan","Brenner, Michael J","32286909"],"abstract":["The novel coronavirus disease 2019 (COVID-19) pandemic has unfolded with remarkable speed, posing unprecedented challenges for health care systems and society. Otolaryngologists have a special role in responding to this crisis by virtue of expertise in airway management. Against the backdrop of nations struggling to contain the virus's spread and to manage hospital strain, otolaryngologists must partner with anesthesiologists and front-line health care teams to provide expert services in high-risk situations while reducing transmission. Airway management and airway endoscopy, whether awake or sedated, expose operators to infectious aerosols, posing risks to staff. This commentary provides background on the outbreak, highlights critical considerations around mitigating infectious aerosol contact, and outlines best practices for airway-related clinical decision making during the COVID-19 pandemic. What otolaryngologists need to know and what actions are required are considered alongside the implications of increasing demand for tracheostomy. Approaches to managing the airway are presented, emphasizing safety of patients and the health care team."],"journal":"Otolaryngol Head Neck Surg","authors":["Balakrishnan, Karthik","Schechtman, Samuel","Hogikyan, Norman D","Teoh, Anthony Y B","McGrath, Brendan","Brenner, Michael J"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32286909","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1177/0194599820919751","keywords":["covid-19","airway management","coronavirus disease","difficult airway","infection","intubation","patient safety","quality improvement","tracheostomy"],"topics":["Prevention"],"weight":1,"_version_":1666138491350679554,"score":156.01012},{"pmid":32424060,"title":"The healthcare worker at risk during the COVID-19 pandemic: a Jewish ethical perspective.","text":["The healthcare worker at risk during the COVID-19 pandemic: a Jewish ethical perspective.","The current COVID-19 pandemic has raised many questions and dilemmas for modern day ethicists and healthcare providers. Are physicians, nurses and other healthcare workers morally obligated to put themselves in harm's way and treat patients during a pandemic, occurring a great risk to themselves, their families and potentially to other patients? The issue was relevant during the 1918 influenza epidemic and more recently severe acute respiratory syndrome epidemic in 2003. Since the risk to the healthcare workers was great, there was tension between the ethical duty and responsibility to treat and the risk to one's own life. This tension was further noted during the 2014 Ebola outbreak in West Africa that left hundreds of healthcare workers dead. The AMA Code of Ethics states that physicians are to 'provide urgent medical care during disasters...even in the face of greater than usual risk to physicians' own safety, health or life.'1 Classic Jewish sources have dealt with this question as well. There is an obligation 'to not stand by idly when your friends life is in danger'; however, the question arises as to whether there are limits to this obligation? Is one required to risk one's own life to save another's? There is a consensus that one is not required but the question open to debate is whether it is praiseworthy to do so. However, regarding healthcare workers, there is agreement for ethical, professional and societal reasons that they are required to put themselves in harm's way to care for their patients.","J Med Ethics","Solnica, Amy","Barski, Leonid","Jotkowitz, Alan","32424060"],"abstract":["The current COVID-19 pandemic has raised many questions and dilemmas for modern day ethicists and healthcare providers. Are physicians, nurses and other healthcare workers morally obligated to put themselves in harm's way and treat patients during a pandemic, occurring a great risk to themselves, their families and potentially to other patients? The issue was relevant during the 1918 influenza epidemic and more recently severe acute respiratory syndrome epidemic in 2003. Since the risk to the healthcare workers was great, there was tension between the ethical duty and responsibility to treat and the risk to one's own life. This tension was further noted during the 2014 Ebola outbreak in West Africa that left hundreds of healthcare workers dead. The AMA Code of Ethics states that physicians are to 'provide urgent medical care during disasters...even in the face of greater than usual risk to physicians' own safety, health or life.'1 Classic Jewish sources have dealt with this question as well. There is an obligation 'to not stand by idly when your friends life is in danger'; however, the question arises as to whether there are limits to this obligation? Is one required to risk one's own life to save another's? There is a consensus that one is not required but the question open to debate is whether it is praiseworthy to do so. However, regarding healthcare workers, there is agreement for ethical, professional and societal reasons that they are required to put themselves in harm's way to care for their patients."],"journal":"J Med Ethics","authors":["Solnica, Amy","Barski, Leonid","Jotkowitz, Alan"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32424060","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1136/medethics-2020-106294","keywords":["codes of/position statements on professional ethics","ethics"],"locations":["West Africa","Jewish","Jewish"],"weight":0,"_version_":1667252837828001792,"score":155.10878},{"pmid":32437032,"title":"Care in the time of coronavirus: Ethical considerations in head and neck oncology.","text":["Care in the time of coronavirus: Ethical considerations in head and neck oncology.","As COVID-19 continues to challenge the practice of head and neck oncology, clinicians are forced to make new decisions in the setting of the pandemic that impact the safety of their patients, their institutions, and themselves. The difficulty inherent in these decisions is compounded by potentially serious ramifications to the welfare of patients and health-care staff, amid a scarcity of data on which to base informed choices. This paper explores the risks of COVID-19 incurred while striving to uphold the standard of care in head and neck oncology. The ethical problems are assessed from the perspective of the patient with cancer, health-care provider, and other patients within the health-care system. While no single management algorithm for head and neck cancer can be universally implemented, a detailed examination of these issues is necessary to formulate ethically sound treatment strategies.","Head Neck","Gordin, Eli A","Day, Andrew","Stankova, Lenka","Heitman, Elizabeth","Sadler, John","32437032"],"abstract":["As COVID-19 continues to challenge the practice of head and neck oncology, clinicians are forced to make new decisions in the setting of the pandemic that impact the safety of their patients, their institutions, and themselves. The difficulty inherent in these decisions is compounded by potentially serious ramifications to the welfare of patients and health-care staff, amid a scarcity of data on which to base informed choices. This paper explores the risks of COVID-19 incurred while striving to uphold the standard of care in head and neck oncology. The ethical problems are assessed from the perspective of the patient with cancer, health-care provider, and other patients within the health-care system. While no single management algorithm for head and neck cancer can be universally implemented, a detailed examination of these issues is necessary to formulate ethically sound treatment strategies."],"journal":"Head Neck","authors":["Gordin, Eli A","Day, Andrew","Stankova, Lenka","Heitman, Elizabeth","Sadler, John"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32437032","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/hed.26272","keywords":["covid-19","cancer","ethics","head and neck","oncology"],"weight":0,"_version_":1667521393588174848,"score":152.63318}]}